Abstract: The present invention relates to polymeric particles comprising a biodegradable polymer, and at least one microorganism in a total concentration of at least 108 CFU/g dry weight that is stable for at least 35 weeks at 30° C. and optionally additional carriers and additives as well as to methods for producing polymeric particles and use thereof.

Abstract: The particle sensor device comprises a substrate, a photodetector, a dielectric on or above the substrate, a source of electromagnetic radiation, and a through-substrate via in the substrate. The through-substrate via is exposed to the environment, in particular to ambient air. A waveguide is arranged in or above the dielectric so that the electromagnetic radiation emitted by the source of electromagnetic radiation is coupled into a portion of the waveguide. A further portion of the waveguide is opposite the photodetector, so that said portions of the waveguide are on different sides of the through-substrate via, and the waveguide traverses the through-substrate via.

Abstract: The present invention relates to polymeric particles comprising a biodegradable polymer, and at least one microorganism in a total concentration of at least 108 CFU/g dry weight that is stable for at least 35 weeks at 30° C. and optionally additional carriers and additives as well as to methods for producing polymeric particles and use thereof.

Abstract: The disclosed subject matter relates to a measuring device for measuring the flow velocity of a flowing fluid, comprising a first measuring element, which is configured to measure the flow velocity of the fluid and includes an interface that can be exposed to the flowing fluid, a second measuring element, which is configured to measure a characteristic property of the fluid and includes an interface that can be exposed to the flowing fluid, and an evaluation unit, which is connected to the first and second measuring elements and configured to correct the flow velocity, measured by the first measuring element, by the influence of the property of the fluid, measured by the second measuring element, on the measurement of the flow velocity. The disclosed subject matter furthermore relates to a measuring probe for such a measuring device.

Abstract: The disclosed subject matter relates to a method and a system for determining a position of a movable agent device in a reflective environment of which a geometric model is known and in which at least one anchor device has a predetermined position, comprising: transmitting a first and a second ultra-wideband pulse signal via a first and a second uni-directional antenna of the anchor device, respectively, and receiving respective received signals via an omni-directional antenna of the agent device; defining a set of candidate positions within said geometric model, and, for each candidate position, calculating a set of multipath components as a function of the geometric model, directivities of the uni-directional antennas and the position of the anchor device; determining a deviation measure between the calculated multipath components and said received signals; and obtaining the position of the agent device as the candidate position with the minimum deviation measure.

Abstract: The present invention relates to a method for producing 2-O-glyceryl-?-D-glucopyranoside (?GG; FIG. 1) from a glucosyl donor and a glucosyl acceptor comprising the steps: providing a sucrose phosphorylase (EC 2.4.1.7), incubating said sucrose phosphorylase with a mixture comprising a glucosyl donor and glycerol as glucosyl acceptor and isolating and/or purifying 2-O-glyceryl-?-D-glucopyranoside.

Abstract: A device for the transcutaneous, in vivo measurement of the concentration of at least one analyte in a living organism includes a catheter which can be introduced into the organism, and a luminescence indicator, which is immobilized on the catheter and which reacts to a change in the concentration of the at least one analyte to be measured with a change in at least one optical property. The luminescence indicator is transcutaneously connected to a source for providing an excitation radiation and a detector for detecting the measuring radiation. The luminescence indicator is immobilized on the outer circumference of the catheter, which is used to dispense a fluid medium, for example a medication, into the organism or to drain a body fluid.

Abstract: The invention refers to a library of bidirectional expression cassettes or expression vectors comprising a repertoire of bidirectional promoter sequences, each expression cassette comprising a promoter sequence operably linked to a first gene in one direction, and operably linked to an oppositely oriented second gene in the other direction which is different from the first gene, and bidirectional Pichia pastoris or CHO cells promoter sequences. The invention further refers to a method of screening or selecting a bidirectional promoter suitable for expressing at least two GOI in a host cell and a kit comprising a) an expression cassette consisting of the first and second genes and a stuffer sequence separating them, which stuffer sequence comprises a recognition site for a type IIS restriction enzyme at both ends; b) the type IIS restriction enzyme; c) and a repertoire of promoter, preferably a promoter library including bidirectional promoters.

Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (?784 to ?719), nucleotides 170 to 191 (?784 to ?763), nucleotides 192 to 213 (?762 to ?741), nucleotides 192 to 210 (?762 to ?744), nucleotides 207 to 209 (?747 to ?745), nucleotides 214 to 235 (?740 to ?719), nucleotides 304 to 350 (?650 to ?604), nucleotides 364 to 393 (?590 to ?561), nucleotides 434 to 508 (?520 to ?446), nucleotides 509 to 551 (?445 to ?403), nucleotides 552 to 560 (?402 to ?394), nucleotides 585 to 617 (?369 to ?337), nucleotides 621 to 660 (?333 to ?294), nucleotides 625 to 683 (?329 to ?271), nucleotides 736 to 741 (?218 to ?213), nucleotides 737 to 738 (?217 to ?216), nucleotides 726 to 755 (?228 to ?199), nucleotides 784 to 800 (?170 to ?154) or nucleotides 823 to 861 (?131 to ?93) of Seq ID No.

Abstract: The present invention relates to compositions comprising an agent, like a polynucleotide, which induces or upregulates expression of UCP1 for use in treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject. The present invention also relates to a method of treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject comprising administrating a composition comprising a polynucleotide which induces or upregulates expression of UCP1.

Abstract: The invention relates to a method for establishing fundamental frequency curves of a plurality of signal sources from a single-channel audio recording of a mix signal, said method including the following steps: a) establishing the spectrogram properties of the pitch states of individual signal sources with use of training data; b) establishing the probabilities of the fundamental frequency combinations of the signal sources contained in the mix signal by a combination of the properties established in a) by means of an interaction model; and c) tracking the fundamental frequency curves of the individual signal sources.

Abstract: A method for analysis of analytes in a sample and to the use of such a method and a method for monitoring progress, or treatment of a disease such as fat-related disease. These analysis methods include the steps of providing the sample, measuring of values of analytes in the sample, calculating of values based on the measured values, identifying and optionally visualizing analytes can particularly be used for monitoring quantitative changes of analytes and for monitoring progress or treatment of a disease such as a fat-related disease.

Abstract: Method for compensating illumination deficiencies in microscopic “shape from focus (SFF)”, wherein firstly the reflectance of the scene is estimated by way of a projector-camera system and then microscopic “shape from focus (SFF)” is applied to a stack of reflectance maps rather than to the original image data.

Abstract: The invention relates to a device for the transcutaneous, in vivo measurement of the concentration of at least one analyte in a living organism, comprising a carrier which can be introduced into the organism, and a luminescence indicator which is immobilized on the carrier and which reacts to a change in the concentration of the analyte to be measured with a change in at least one optical property, wherein the luminescence indicator is transcutaneously connected to a source for providing the excitation radiation and a detector for detecting the measuring radiation. According to the invention, the luminescence indicator is immobilized on the outer circumference of a catheter, which is used to dispense a fluid medium, for example a medicament, into the organism or to suck up a body fluid.

Abstract: An assay library comprising 14 fluorescently labeled phosphonate esters which act as serine hydrolase inhibitors is provided as an analytical tool enabling activity based identification of serine hydrolases and characterization of enzyme preparations, protein mixtures and complex proteome samples.

Abstract: A sensor system being is located in an environment composed of a first medium, where waves propagate with a first phase velocity, the sensor system including at least one main enclosure and a sensor array with at least two sensors, said sensor array being arranged inside the main enclosure, wherein the space inside the main enclosure between the sensor array and the inner surface of the main enclosure is filled with a second medium, in which waves propagate with a second phase velocity, the second phase velocity being different from the first velocity.

Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (?784 to ?719), nucleotides 170 to 191 (?784 to ?763), nucleotides 192 to 213 (?762 to ?741), nucleotides 192 to 210 (?762 to ?744), nucleotides 207 to 209 (?747 to ?745), nucleotides 214 to 235 (?740 to ?719), nucleotides 304 to 350 (?650 to ?604), nucleotides 364 to 393 (?590 to ?561), nucleotides 434 to 508 (?520 to ?446), nucleotides 509 to 551 (?445 to ?403), nucleotides 552 to 560 (?402 to ?394), nucleotides 585 to 617 (?369 to ?337), nucleotides 621 to 660 (?333 to ?294), nucleotides 625 to 683 (?329 to ?271), nucleotides 736 to 741 (?218 to ?213), nucleotides 737 to 738 (?217 to ?216), nucleotides 726 to 755 (?228 to ?199), nucleotides 784 to 800 (?170 to ?154) or nucleotides 823 to 861 (?131 to ?93) of Seq ID No.

Abstract: The invention relates to a method which makes use of the Zeeman effect for measuring magnetic fields, by way of dark resonances. According to said method, a measuring cell (14) is exposed to the magnetic field (B) to be measured and contains the atoms of a measuring medium in a buffer gas, a radiation source (11) being provided for exciting the atoms by radiation and being connected to the modulation frequency generator and emitting electromagnetic radiation with different frequencies. A frequency detector (17) is mounted downstream of the measuring cell (14) and comprises a control loop (18) for the frequency tuning to a dark resonance frequency.

Abstract: The invention relates to oxidized phospholipids having one of the general formulas (I) or (II) wherein A=O, C, NH, or S; B?O, C, NH, or S; and R2 is selected from the group consisting of —CO—(CH2)n—CH3; —CO—(CH2)b—CHO; and —CO—(CH2)n—COOH, with n=3-7, with the proviso that in general formula (I), R1 is selected from the group consisting of —CH2—(CH2)n—X; a —CO—(CH2)n—X with n=5-11, wherein X is a fluorophore; and in general formula (II), R1 is selected from the group consisting of —CH?CH—(CH2)n—CH3 with n=9-15; —(CH2)n—CH3 with n=11-17; and —CO—(CH2)n—CH3 with n=10-16; and R3 is selected from the group consisting of —CO—(CH2)n—X; and —SO2—(CH2)n—X, with n=0-5, wherein X is a fluorophore.

Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (?784 to ?719), nucleotides 170 to 191 (?784 to ?763), nucleotides 192 to 213 (?762 to ?741), nucleotides 192 to 210 (?762 to ?744), nucleotides 207 to 209 (?747 to ?745), nucleotides 214 to 235 (?740 to ?719), nucleotides 304 to 350 (?650 to ?604), nucleotides 364 to 393 (?590 to ?561), nucleotides 434 to 508 (?520 to ?446), nucleotides 509 to 551 (?445 to ?403), nucleotides 552 to 560 (?402 to ?394), nucleotides 585 to 617 (?369 to ?337), nucleotides 621 to 660 (?333 to ?294), nucleotides 625 to 683 (?329 to ?271), nucleotides 736 to 741 (?218 to ?213), nucleotides 737 to 738 (?217 to ?216), nucleotides 726 to 755 (?228 to ?199), nucleotides 784 to 800 (?170 to ?154) or nucleotides 823 to 861 (?131 to ?93) of Seq ID No.